Oxford Biomedica plc (OXBDF)
OTCMKTS · Delayed Price · Currency is USD
11.34
+0.09 (0.78%)
At close: Feb 11, 2026
Oxford Biomedica Revenue
Oxford Biomedica had revenue of 73.22M GBP in the half year ending June 30, 2025, with 70.04% growth. This brings the company's revenue in the last twelve months to 151.21M, up 55.44% year-over-year. In the year 2024, Oxford Biomedica had annual revenue of 128.80M with 43.84% growth.
Revenue (ttm)
151.21M GBP
Revenue Growth
+55.44%
P/S Ratio
6.49
Revenue / Employee
168.02K GBP
Employees
900
Market Cap
1.35B USD
Revenue Chart
* This company reports financials in GBP.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 128.80M | 39.26M | 43.84% |
| Dec 31, 2023 | 89.54M | -50.45M | -36.04% |
| Dec 31, 2022 | 139.99M | -2.81M | -1.97% |
| Dec 31, 2021 | 142.80M | 55.07M | 62.77% |
| Dec 31, 2020 | 87.73M | 23.67M | 36.95% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| BioStem Technologies | 292.21M |
| Vaxart | 148.20M |
| Silence Therapeutics | 25.83M |
| Nuo Therapeutics | 2.61M |
| Northwest Biotherapeutics | 937.00K |
| ZIVO Bioscience | 209.03K |
| Arch Biopartners | 198.11K |
Oxford Biomedica News
- 8 days ago - Oxford Biomedica Signs Multi-Year Commercial Supply Deal With Bristol Myers Squibb - Nasdaq
- 4 weeks ago - UK's Oxford Biomedica confirms unsolicited bid from funds managed by EQT - Reuters
- 3 months ago - Oxford Biomedica plc (OXBDF) Presents at Jefferies London Healthcare Conference 2025 - Slideshow - Seeking Alpha
- 4 months ago - Oxford Biomedica Acquires $4.5 Mln North Carolina Gene Therapy Facility - Nasdaq
- 5 months ago - Oxford BioMedica PLC (OXBDF) (H1 2025) Earnings Call Highlights: Strong Revenue Growth and ... - GuruFocus
- 5 months ago - Half Year 2025 Oxford Biomedica PLC Earnings Call Transcript - GuruFocus
- 5 months ago - Oxford Biomedica plc (OXBDF) Q2 2025 Earnings Call Transcript - Seeking Alpha
- 5 months ago - Oxford Biomedica plc 2025 Q2 - Results - Earnings Call Presentation - Seeking Alpha